ABIO
Income statement / Annual
Last year (2025), ARCA biopharma Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, ARCA biopharma Inc's net income was -$105.43 M.
See ARCA biopharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2025 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$111.00 K
|
$114.00 K
|
$91.00 K
|
$93.00 K
|
$89.00 K
|
$22.00 K
|
$27.00 K
|
$24.00 K
|
$0.00
|
| Gross Profit |
$0.00
|
-$111.00 K
|
-$114.00 K
|
-$91.00 K
|
-$93.00 K
|
-$89.00 K
|
-$22.00 K
|
-$27.00 K
|
-$24.00 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$100.64 M
|
$1.01 M
|
$4.75 M
|
$13.83 M
|
$4.99 M
|
$1.83 M
|
$4.24 M
|
$14.08 M
|
$12.35 M
|
$7.06 M
|
| General & Administrative Expenses |
$21.41 M
|
$6.28 M
|
$5.85 M
|
$5.50 M
|
$4.77 M
|
$3.98 M
|
$3.88 M
|
$4.64 M
|
$4.27 M
|
$4.39 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$21.41 M
|
$6.28 M
|
$5.85 M
|
$5.50 M
|
$4.77 M
|
$3.98 M
|
$3.88 M
|
$4.64 M
|
$4.27 M
|
$4.39 M
|
| Other Expenses |
$0.00
|
-$111.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$122.05 M
|
$7.19 M
|
$10.60 M
|
$19.34 M
|
$9.77 M
|
$5.81 M
|
$8.12 M
|
$18.71 M
|
$16.61 M
|
$11.46 M
|
| Cost And Expenses |
$0.00
|
$7.30 M
|
$10.60 M
|
$19.34 M
|
$9.77 M
|
$5.81 M
|
$8.12 M
|
$18.71 M
|
$16.61 M
|
$11.46 M
|
| Interest Income |
$16.63 M
|
$1.96 M
|
$675.00 K
|
$13.00 K
|
$28.00 K
|
$172.00 K
|
$162.00 K
|
$167.00 K
|
$169.00 K
|
$14.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$675.00 K
|
$0.00
|
$9.00 K
|
$7.00 K
|
$8.00 K
|
$6.00 K
|
$0.00
|
$4.00 K
|
| Depreciation & Amortization |
$83.00 K
|
$15.00 K
|
$114.00 K
|
$91.00 K
|
$93.00 K
|
$18.00 K
|
$22.00 K
|
$27.00 K
|
$24.00 K
|
$19.00 K
|
| EBITDA |
-$122.05 M |
-$7.12 M |
-$9.73 M |
-$19.24 M |
-$9.65 M |
-$5.62 M |
-$7.93 M |
-$18.55 M |
-$16.12 M |
-$11.42 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.62 M
|
$1.96 M
|
-$85.00 K
|
$13.00 K
|
$19.00 K
|
$165.00 K
|
$154.00 K
|
$161.00 K
|
$169.00 K
|
$10.00 K
|
| Income Before Tax |
-$105.43 M
|
-$5.34 M
|
-$9.93 M
|
-$19.32 M
|
-$9.75 M
|
-$5.65 M
|
-$7.96 M
|
-$18.55 M
|
-$16.44 M
|
-$11.45 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$670.00 K
|
-$91.00 K
|
-$9.00 K
|
-$167.00 K
|
-$31.00 K
|
-$61.00 K
|
$188.00 K
|
$14.00 K
|
| Net Income |
-$105.43 M
|
-$5.34 M
|
-$9.93 M
|
-$19.32 M
|
-$9.74 M
|
-$5.48 M
|
-$7.93 M
|
-$18.49 M
|
-$16.44 M
|
-$11.45 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-154.03 |
-0.37 |
-0.69 |
-1.39 |
-2.07 |
-4.15 |
-10.31 |
-31.91 |
-32.68 |
-22.76 |
| EPS Diluted |
-154.03 |
-0.37 |
-0.69 |
-1.39 |
-2.07 |
-4.15 |
-10.31 |
-31.91 |
-32.68 |
-32.76 |
| Weighted Average Shares Out |
$45.61 K
|
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$1.32 M
|
$769.39 K
|
$579.52 K
|
$503.75 K
|
$502.96 K
|
| Weighted Average Shares Out Diluted |
$45.61 K
|
$14.42 M
|
$14.41 M
|
$13.90 M
|
$4.71 M
|
$1.32 M
|
$769.40 K
|
$579.53 K
|
$503.75 K
|
$502.96 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
